Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity

Journal of Medicinal Chemistry

Volumn 44, Issue 18, 2001, Pages 3001-3013

  Carceller, E ^a   Salas, J ^a   Merlos, M ^a   Giral, M ^a   Ferrando, R ^a   Escamilla, I ^a   Ramis, J ^a   Garcia Rafanell J ^a   Forn, J ^a  

^a Grupo Uriach   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(1 ACYL 4 PIPERIDYL)METHYL] 1H 2 METHYLIMIDAZO[4,5 C]PYRIDINE; AZO COMPOUND; BB 823; LEXIPAFANT; MESALAZINE; PRODRUG; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG; UR 12715; UR 12746;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; IC 50; NONHUMAN; RAT; ULCERATIVE COLITIS;

AMINES; AMINOSALICYLIC ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZA COMPOUNDS; AZO COMPOUNDS; COLITIS, ULCERATIVE; DRUG EVALUATION, PRECLINICAL; FEMALE; HYPOTENSION; IMIDAZOLES; MALE; MESALAMINE; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION; PRODRUGS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRINITROBENZENESULFONIC ACID;

EID: 0035974705     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010852p     Document Type: Article

References (28)

1. Inflammatory bowel disease
2. Soluble mediators and the interaction of drugs in IBD
3. Newer 5-aminosalicylic acid based drugs in chronic inflamatory bowel disease
4. Colon-specific delivery
5. Balsalazide
6. Role of cytokines and platelet-activating factor in human inflamed colonic mucosa
7. Cytokines and platelet-activating factor in human inflamed colonic mucosa
8. Platelet activating factor: Release from colonic mucosa in patients with ulcerative colitis and its effects on colonic secretion
9. The role of platelet-activating factor in the pathogenesis of gastrointestinal disease
10. Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: A randomized controlled trial
11. Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists
12. (Pyridylcyanomethyl)piperazines as orally active PAF-antagonists
13. Synthesis and structure activity relationships of 1-Acyl-4-((2-methyl-3-py-ridyl)cyanomethyl)piperazines as PAF-antagonists
14. Design, synthesis and structure - Activity relationship studies of novel 1-[(1-Acyl-4piperidyl)methyl]-1H-2-methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists
15. A partial pharmacophore for the Platelet Activating Factor (PAF) receptor
16. Structure - Activity relationships for BB-823 and related PAF antagonists
17. Aryl participation in the solvolysis of some gem-dimethyl-substituted 4-Aryl-1-alkyl p-bromobenzenesulfonates
18. Selective muscarinic antagonists. Y. Synthesis and antimuscarinic properties of 4-piperidyl benzhydrylcarbamate derivatives
19. Metalation of N-(Pivaloyl)- and N-(tert-butoxycarbonyl)difluoroanilines: Regiocontrol by fluorine in the synthesis of 4-methoxycarbonyl derivatives
20. Aggregation of blood platelets by adenosine diphosphate and its reversal
21. The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021
22. Thieno-triazolo-1,4-diazepines as antagonists of Platelet-Aactivating Factor: Present status
23. Pharmacological actions of WEB-2086, a new specific antagonist of platelet activating factor
24. Intestinal antiinflammatory activity of UR-12746 on a rat model of colitis
25. Oral administration of UR-12746 is able of ameliorate experimental colitis in rats
26. Intestinal antiinflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat
27. Disruption of colonic electrolyte transport in experimental colitis